Does Delta Hemoglobin-Albumin-Lymphocyte Platelet (HALP) Score Predict the Risk of Early Progression in Patients Treated with CDK4/6 Inhibitors?
Aim: This study aims to determine the predictive value of dynamic change in hemoglobin-albumin-lymphocyte-platelet (HALP) score on treatment response in hormone-positive metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors. Materials and Methods: This study was d...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Yayincilik
2024-12-01
|
| Series: | Namık Kemal Tıp Dergisi |
| Subjects: | |
| Online Access: | https://namikkemalmedj.com/articles/does-delta-hemoglobin-albumin-lymphocyte-platelet-halp-score-predict-the-risk-of-early-progression-in-patients-treated-with-cdk46-inhibitors/doi/nkmj.galenos.2024.12599 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846116281107873792 |
|---|---|
| author | Burcu Belen GÜLBAĞCI Miraç ÖZEN Esra ÖZEN ENGİN Fatma AKDAĞ KAHVECİOĞLU Esra ÇİFTÇİ İlhan HACIBEKİROĞLU |
| author_facet | Burcu Belen GÜLBAĞCI Miraç ÖZEN Esra ÖZEN ENGİN Fatma AKDAĞ KAHVECİOĞLU Esra ÇİFTÇİ İlhan HACIBEKİROĞLU |
| author_sort | Burcu Belen GÜLBAĞCI |
| collection | DOAJ |
| description | Aim: This study aims to determine the predictive value of dynamic change in hemoglobin-albumin-lymphocyte-platelet (HALP) score on treatment response in hormone-positive metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors.
Materials and Methods: This study was designed retrospectively. Between January 1, 2020, and September 30, 2023, 104 patients diagnosed with metastatic hormone receptor-positive/human epidermal growth factor 2 receptor negative breast cancer were treated with CDK4/6 inhibitors plus endocrine therapies at Sakarya University Training and Research Hospital. Patients were divided into two groups according to whether there was progression at the initial response evaluation. Factors that could predict treatment response between the two groups were compared with regression analysis.
Results: The median HALP score in patients was 34.08 (23.46-45.08) before treatment and 28.3 (19.24-42.61) at first response evaluation. Delta HALP was ≤0 for sixty-four (61.5%) patients, >0 for 40 patients (38.5%). There was no statistical difference in delta HALP score between groups with and without progression at the first response evaluation (p=0.334). The presence of liver metastasis and treatment line significantly affect the early progression by univariate and multivariate regression analysis (p=0.031 and p=0.016, respectively).
Conclusion: Our study has found that the delta HALP score does not predict early progression. The presence of liver metastasis and later treatment line were found to be statistically significant with early progression. These data are compatible with the literature. |
| format | Article |
| id | doaj-art-e4f34ef8e95142e8b1d561ffbf43fbd4 |
| institution | Kabale University |
| issn | 2587-0262 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Galenos Yayincilik |
| record_format | Article |
| series | Namık Kemal Tıp Dergisi |
| spelling | doaj-art-e4f34ef8e95142e8b1d561ffbf43fbd42024-12-19T08:36:03ZengGalenos YayincilikNamık Kemal Tıp Dergisi2587-02622024-12-0112426026510.4274/nkmj.galenos.2024.12599Does Delta Hemoglobin-Albumin-Lymphocyte Platelet (HALP) Score Predict the Risk of Early Progression in Patients Treated with CDK4/6 Inhibitors?Burcu Belen GÜLBAĞCI0https://orcid.org/0000-0002-5720-8254Miraç ÖZEN1https://orcid.org/0000-0002-1934-0190Esra ÖZEN ENGİN2https://orcid.org/0000-0002-5225-1456Fatma AKDAĞ KAHVECİOĞLU3https://orcid.org/0000-0003-4656-0970Esra ÇİFTÇİ4https://orcid.org/0000-0001-6106-7733İlhan HACIBEKİROĞLU5https://orcid.org/0000-0002-0333-7405Tekirdağ İsmail Fehmi Cumalıoğlu State Hospital, Clinic of Medical Oncology, Tekirdağ, TurkeyAsklepios Clinic Triberg, Clinic of Hematology, Schwarzwald, GermanySakarya University Training and Research Hospital, Clinic of Medical Oncology, Sakarya, TurkeySakarya University Training and Research Hospital, Clinic of Medical Oncology, Sakarya, TurkeySakarya University Training and Research Hospital, Clinic of Nuclear Medicine, Sakarya, TurkeySakarya University Training and Research Hospital, Clinic of Medical Oncology, Sakarya, TurkeyAim: This study aims to determine the predictive value of dynamic change in hemoglobin-albumin-lymphocyte-platelet (HALP) score on treatment response in hormone-positive metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors. Materials and Methods: This study was designed retrospectively. Between January 1, 2020, and September 30, 2023, 104 patients diagnosed with metastatic hormone receptor-positive/human epidermal growth factor 2 receptor negative breast cancer were treated with CDK4/6 inhibitors plus endocrine therapies at Sakarya University Training and Research Hospital. Patients were divided into two groups according to whether there was progression at the initial response evaluation. Factors that could predict treatment response between the two groups were compared with regression analysis. Results: The median HALP score in patients was 34.08 (23.46-45.08) before treatment and 28.3 (19.24-42.61) at first response evaluation. Delta HALP was ≤0 for sixty-four (61.5%) patients, >0 for 40 patients (38.5%). There was no statistical difference in delta HALP score between groups with and without progression at the first response evaluation (p=0.334). The presence of liver metastasis and treatment line significantly affect the early progression by univariate and multivariate regression analysis (p=0.031 and p=0.016, respectively). Conclusion: Our study has found that the delta HALP score does not predict early progression. The presence of liver metastasis and later treatment line were found to be statistically significant with early progression. These data are compatible with the literature.https://namikkemalmedj.com/articles/does-delta-hemoglobin-albumin-lymphocyte-platelet-halp-score-predict-the-risk-of-early-progression-in-patients-treated-with-cdk46-inhibitors/doi/nkmj.galenos.2024.12599cyclin-dependent kinase (cdk) 4/6 inhibitorsdelta halp scorehemoglobin-albumin-lymphocyte-platelet (halp) score |
| spellingShingle | Burcu Belen GÜLBAĞCI Miraç ÖZEN Esra ÖZEN ENGİN Fatma AKDAĞ KAHVECİOĞLU Esra ÇİFTÇİ İlhan HACIBEKİROĞLU Does Delta Hemoglobin-Albumin-Lymphocyte Platelet (HALP) Score Predict the Risk of Early Progression in Patients Treated with CDK4/6 Inhibitors? Namık Kemal Tıp Dergisi cyclin-dependent kinase (cdk) 4/6 inhibitors delta halp score hemoglobin-albumin-lymphocyte-platelet (halp) score |
| title | Does Delta Hemoglobin-Albumin-Lymphocyte Platelet (HALP) Score Predict the Risk of Early Progression in Patients Treated with CDK4/6 Inhibitors? |
| title_full | Does Delta Hemoglobin-Albumin-Lymphocyte Platelet (HALP) Score Predict the Risk of Early Progression in Patients Treated with CDK4/6 Inhibitors? |
| title_fullStr | Does Delta Hemoglobin-Albumin-Lymphocyte Platelet (HALP) Score Predict the Risk of Early Progression in Patients Treated with CDK4/6 Inhibitors? |
| title_full_unstemmed | Does Delta Hemoglobin-Albumin-Lymphocyte Platelet (HALP) Score Predict the Risk of Early Progression in Patients Treated with CDK4/6 Inhibitors? |
| title_short | Does Delta Hemoglobin-Albumin-Lymphocyte Platelet (HALP) Score Predict the Risk of Early Progression in Patients Treated with CDK4/6 Inhibitors? |
| title_sort | does delta hemoglobin albumin lymphocyte platelet halp score predict the risk of early progression in patients treated with cdk4 6 inhibitors |
| topic | cyclin-dependent kinase (cdk) 4/6 inhibitors delta halp score hemoglobin-albumin-lymphocyte-platelet (halp) score |
| url | https://namikkemalmedj.com/articles/does-delta-hemoglobin-albumin-lymphocyte-platelet-halp-score-predict-the-risk-of-early-progression-in-patients-treated-with-cdk46-inhibitors/doi/nkmj.galenos.2024.12599 |
| work_keys_str_mv | AT burcubelengulbagci doesdeltahemoglobinalbuminlymphocyteplatelethalpscorepredicttheriskofearlyprogressioninpatientstreatedwithcdk46inhibitors AT miracozen doesdeltahemoglobinalbuminlymphocyteplatelethalpscorepredicttheriskofearlyprogressioninpatientstreatedwithcdk46inhibitors AT esraozenengin doesdeltahemoglobinalbuminlymphocyteplatelethalpscorepredicttheriskofearlyprogressioninpatientstreatedwithcdk46inhibitors AT fatmaakdagkahvecioglu doesdeltahemoglobinalbuminlymphocyteplatelethalpscorepredicttheriskofearlyprogressioninpatientstreatedwithcdk46inhibitors AT esraciftci doesdeltahemoglobinalbuminlymphocyteplatelethalpscorepredicttheriskofearlyprogressioninpatientstreatedwithcdk46inhibitors AT ilhanhacibekiroglu doesdeltahemoglobinalbuminlymphocyteplatelethalpscorepredicttheriskofearlyprogressioninpatientstreatedwithcdk46inhibitors |